Florian Rieder

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6743853/publications.pdf

Version: 2024-02-01

156 papers

11,412 citations

45 h-index 102 g-index

158 all docs

158 docs citations

158 times ranked 10076 citing authors

#	Article	IF	CITATIONS
1	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. Journal of Crohn's and Colitis, 2017, 11, 3-25.	0.6	1,547
2	Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. Journal of Crohn's and Colitis, 2017, 11, 649-670.	0.6	1,324
3	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. Journal of Crohn's and Colitis, 2019, 13, 144-164K.	0.6	958
4	Fibrosis: from mechanisms to medicines. Nature, 2020, 587, 555-566.	13.7	746
5	Crohn's disease complicated by strictures: a systematic review. Gut, 2013, 62, 1072-1084.	6.1	379
6	Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases. Gastroenterology, 2017, 152, 340-350.e6.	0.6	317
7	Intestinal fibrosis in IBD—a dynamic, multifactorial process. Nature Reviews Gastroenterology and Hepatology, 2009, 6, 228-235.	8.2	271
8	Wound healing and fibrosis in intestinal disease. Gut, 2007, 56, 130-139.	6.1	262
9	Inflammation-Induced Endothelial-to-Mesenchymal Transition. American Journal of Pathology, 2011, 179, 2660-2673.	1.9	262
10	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. Journal of Crohn's and Colitis, 2019, 13, 273-284.	0.6	250
11	Cellular and molecular mechanisms of intestinal fibrosis. World Journal of Gastroenterology, 2012, 18, 3635.	1.4	209
12	European Crohn's and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn's Disease. Journal of Crohn's and Colitis, 2016, 10, 873-885.	0.6	185
13	Assessment of Crohn's disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review. Gut, 2019, 68, 1115-1126.	6.1	178
14	A Pooled Analysis of Efficacy, Safety, and Long-term Outcome of Endoscopic Balloon Dilation Therapy for Patients with Stricturing CrohnE ¹ / ₄ 's Disease. Inflammatory Bowel Diseases, 2017, 23, 133-142.	0.9	166
15	An expert consensus to standardise definitions, diagnosis and treatment targets for antiâ€fibrotic stricture therapies in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2018, 48, 347-357.	1.9	157
16	Intestinal fibrosis in inflammatory bowel disease â€" Current knowledge and future perspectives. Journal of Crohn's and Colitis, 2008, 2, 279-290.	0.6	130
17	Mechanisms of initiation and progression of intestinal fibrosis in IBD. Scandinavian Journal of Gastroenterology, 2015, 50, 53-65.	0.6	126
18	Gastroesophageal Reflux Disease–Associated Esophagitis Induces Endogenous Cytokine Production Leading to Motor Abnormalities. Gastroenterology, 2007, 132, 154-165.	0.6	125

#	Article	IF	Citations
19	Evidence for a role of epithelial mesenchymal transition during pathogenesis of fistulae in Crohnʽs disease. Inflammatory Bowel Diseases, 2008, 14, 1514-1527.	0.9	117
20	The Mesenteric Fat and Intestinal Muscle Interface: Creeping Fat Influencing Stricture Formation in Crohn's Disease. Inflammatory Bowel Diseases, 2019, 25, 421-426.	0.9	115
21	T-Helper 2 Cytokines, Transforming Growth Factor \hat{l}^21 , and Eosinophil Products Induce Fibrogenesis and Alter Muscle Motility in Patients With Eosinophilic Esophagitis. Gastroenterology, 2014, 146, 1266-1277.e9.	0.6	114
22	Fibrosis in ulcerative colitis is directly linked to severity and chronicity of mucosal inflammation. Alimentary Pharmacology and Therapeutics, 2018, 47, 922-939.	1.9	112
23	The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy. Journal of Crohn's and Colitis, 2019, 13, 541-554.	0.6	112
24	Animal models of intestinal fibrosis: new tools for the understanding of pathogenesis and therapy of human disease. American Journal of Physiology - Renal Physiology, 2012, 303, G786-G801.	1.6	111
25	Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. American Journal of Physiology - Renal Physiology, 2010, 298, G571-G581.	1.6	99
26	Fibrosis in Ulcerative Colitis. Inflammatory Bowel Diseases, 2014, 20, 2198-2206.	0.9	93
27	The emerging role of histologic disease activity assessment in ulcerative colitis. Gastrointestinal Endoscopy, 2018, 88, 887-898.	0.5	93
28	Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn $\hat{E}\frac{1}{4}$ s disease behavior. Inflammatory Bowel Diseases, 2010, 16, 263-274.	0.9	87
29	Safety and efficacy of endoscopic dilation for primary and anastomotic Crohn's disease strictures. Journal of Crohn's and Colitis, 2014, 8, 392-400.	0.6	81
30	Characterization of Degree of Intestinal Fibrosis in Patients with Crohn Disease by Using Magnetization Transfer MR Imaging. Radiology, 2018, 287, 494-503.	3.6	81
31	Serum anti-glycan antibodies predict complicated Crohn $\hat{E}^1\!\!/\!\!4$ s disease behavior. Inflammatory Bowel Diseases, 2010, 16, 1367-1375.	0.9	79
32	Novel PPARÎ ³ Modulator GED-0507-34 Levo Ameliorates Inflammation-driven Intestinal Fibrosis. Inflammatory Bowel Diseases, 2016, 22, 279-292.	0.9	68
33	Medical therapy of stricturing Crohn's disease: what the gut can learn from other organs - a systematic review. Fibrogenesis and Tissue Repair, 2014, 7, 5.	3.4	65
34	Results of the 4th Scientific Workshop of the ECCO (Group II): Markers of intestinal fibrosis in inflammatory bowel disease. Journal of Crohn's and Colitis, 2014, 8, 1166-1178.	0.6	65
35	The Origin and Contribution of Cancer-Associated Fibroblasts in Colorectal Carcinogenesis. Gastroenterology, 2022, 162, 890-906.	0.6	63
36	Circulating Antibodies against Bacterial Wall Products: Are There Arguments for Early Immunosuppression?. Digestive Diseases, 2012, 30, 55-66.	0.8	61

#	Article	IF	CITATIONS
37	Predictors of fibrostenotic Crohn's disease. Inflammatory Bowel Diseases, 2011, 17, 2000-2007.	0.9	60
38	Pathogenesis of fibrostenosing Crohn's disease. Translational Research, 2019, 209, 39-54.	2.2	60
39	The Gut Microbiome in Intestinal Fibrosis: Environmental Protector or Provocateur?. Science Translational Medicine, 2013, 5, 190ps10.	5.8	58
40	IL-36 in chronic inflammation and fibrosis â€" bridging the gap?. Journal of Clinical Investigation, 2021, 131, .	3.9	57
41	Development and Validation of a Novel Computed-Tomography Enterography Radiomic Approach for Characterization of Intestinal Fibrosis in Crohn's Disease. Gastroenterology, 2021, 160, 2303-2316.e11.	0.6	57
42	An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials. Gastroenterology, 2021, 160, 2291-2302.	0.6	57
43	Real-Time Shear Wave Ultrasound Elastography Differentiates Fibrotic from Inflammatory Strictures in Patients with Crohn's Disease. Inflammatory Bowel Diseases, 2018, 24, 2183-2190.	0.9	53
44	Results of the 2nd Scientific Workshop of the ECCO (III): Basic mechanisms of intestinal healing. Journal of Crohn's and Colitis, 2012, 6, 373-375.	0.6	50
45	Intestinal fibrosis. Current Opinion in Gastroenterology, 2017, 33, 239-245.	1.0	50
46	Histopathology Scoring Systems of Stenosis Associated With Small Bowel Crohn's Disease: A Systematic Review. Gastroenterology, 2020, 158, 137-150.e1.	0.6	50
47	Challenges in the Pathophysiology, Diagnosis, and Management of Intestinal Fibrosis in Inflammatory Bowel Disease. Gastroenterology, 2022, 162, 26-31.	0.6	48
48	Novel mechanisms and clinical trial endpoints in intestinal fibrosis*. Immunological Reviews, 2021, 302, 211-227.	2.8	47
49	Mechanisms of Tissue Remodeling in Inflammatory Bowel Disease. Digestive Diseases, 2013, 31, 186-193.	0.8	46
50	Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science. Current Opinion in Gastroenterology, 2008, 24, 462-468.	1.0	45
51	Emerging treatment options for extraintestinal manifestations in IBD. Gut, 2021, 70, 796-802.	6.1	45
52	Degree of Creeping Fat Assessed by Computed Tomography Enterography is Associated with Intestinal Fibrotic Stricture in Patients with Crohn's Disease: A Potentially Novel Mesenteric Creeping Fat Index. Journal of Crohn's and Colitis, 2021, 15, 1161-1173.	0.6	45
53	Fibrostenotic strictures in Crohn's disease. Intestinal Research, 2020, 18, 379-401.	1.0	45
54	Pathogenesis of Intestinal Fibrosis in Inflammatory Bowel Disease and Perspectives for Therapeutic Implication. Digestive Diseases, 2017, 35, 25-31.	0.8	44

#	Article	IF	CITATIONS
55	Challenges in IBD Research: Preclinical Human IBD Mechanisms. Inflammatory Bowel Diseases, 2019, 25, S5-S12.	0.9	44
56	Yersiniabactin-Producing Adherent/Invasive Escherichia coli Promotes Inflammation-Associated Fibrosis in Gnotobiotic $\langle i \rangle$ Il 10 $\langle sup \rangle$ â^'/â^' $\langle sup \rangle$ $\langle i \rangle$ Mice. Infection and Immunity, 2019, 87, .	1.0	38
57	Systematic review with metaâ€analysis: efficacy of balloonâ€assisted enteroscopy for dilation of small bowel Crohn's disease strictures. Alimentary Pharmacology and Therapeutics, 2020, 52, 1104-1116.	1.9	36
58	Serologic Antiglycan Antibodies in Inflammatory Bowel Disease. American Journal of Gastroenterology, 2011, 106, 406-412.	0.2	35
59	Prostaglandin E2 inhibits migration of colonic lamina propria fibroblasts. Inflammatory Bowel Diseases, 2010, 16, 1505-1513.	0.9	33
60	Heterogeneity in endoscopic treatment of Crohn's disease-associated strictures: An international inflammatory bowel disease specialist survey. Journal of Gastroenterology, 2016, 51, 939-948.	2.3	33
61	Activated intestinal muscle cells promote preadipocyte migration: a novel mechanism for creeping fat formation in Crohn's disease. Gut, 2022, 71, 55-67.	6.1	33
62	Reversibility of Stricturing Crohn's Diseaseâ€"Fact or Fiction?. Inflammatory Bowel Diseases, 2016, 22, 241-247.	0.9	32
63	Selective deletion of MyD88 signaling in \hat{l}_{\pm} -SMA positive cells ameliorates experimental intestinal fibrosis via post-transcriptional regulation. Mucosal Immunology, 2020, 13, 665-678.	2.7	32
64	Efficacy, Safety, and Long-term Outcome of Serial Endoscopic Balloon Dilation for Upper Gastrointestinal Crohn's Disease-associated Strictures—A Cohort Study. Journal of Crohn's and Colitis, 2017, 11, 1044-1051.	0.6	31
65	Efficacy of Endoscopic Dilation of Gastroduodenal Crohn's Disease Strictures: A Systematic Review and Meta-Analysis of Individual Patient Data. Clinical Gastroenterology and Hepatology, 2019, 17, 2514-2522.e8.	2.4	31
66	Development of antifibrotic therapy for stricturing Crohn's disease: lessons from randomized trials in other fibrotic diseases. Physiological Reviews, 2022, 102, 605-652.	13.1	31
67	Vaccination in Patients with Inflammatory Bowel Diseases. Digestion, 2020, 101, 58-68.	1.2	29
68	International consensus to standardise histopathological scoring for small bowel strictures in Crohn's disease. Gut, 2022, 71, 479-486.	6.1	29
69	Characterization of Changes in Serum Anti-Glycan Antibodies in Crohn's Disease – a Longitudinal Analysis. PLoS ONE, 2011, 6, e18172.	1.1	29
70	Systematic review: medical therapy for fibrostenosing Crohn's disease. Alimentary Pharmacology and Therapeutics, 2020, 51, 1233-1246.	1.9	26
71	Viewpoints on Acid-Induced Inflammatory Mediators in Esophageal Mucosa. Journal of Neurogastroenterology and Motility, 2010, 16, 374-388.	0.8	25
72	Hemoglobin and Hematocrit Levels in the Prediction of Complicated Crohn's Disease Behavior – A Cohort Study. PLoS ONE, 2014, 9, e104706.	1.1	25

#	Article	IF	Citations
73	Serologic Anti-GP2 Antibodies Are Associated with Genetic Polymorphisms, Fibrostenosis, and Need for Surgical Resection in Crohn's Disease. Inflammatory Bowel Diseases, 2016, 22, 2648-2657.	0.9	25
74	Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's Disease: A Systematic Review. Clinical Gastroenterology and Hepatology, 2022, 20, 817-846.e10.	2.4	25
75	Hypoalbuminaemia, Not Biologic Exposure, Is Associated with Postoperative Complications in Crohn's Disease Patients Undergoing Ileocolic Resection. Journal of Crohn's and Colitis, 2021, 15, 1142-1151.	0.6	25
76	Clinical Utility of Anti-Glycan Antibodies in Pediatric Crohn $\hat{E}^{1}/4$ s Disease in Comparison with An Adult Cohort. Inflammatory Bowel Diseases, 2012, 18, 1221-1231.	0.9	24
77	Treatments for Crohn's Disease–Associated Bowel Damage: A Systematic Review. Clinical Gastroenterology and Hepatology, 2019, 17, 847-856.	2.4	23
78	Real-World Effectiveness and Safety of Ustekinumab in Elderly Crohn's Disease Patients. Digestive Diseases and Sciences, 2022, 67, 3138-3147.	1.1	23
79	The Future of Precision Medicine to Predict Outcomes and Control Tissue Remodeling in Inflammatory Bowel Disease. Gastroenterology, 2022, 162, 1525-1542.	0.6	23
80	Natural history, diagnosis and treatment approach to fibrostenosing Crohn's disease. United European Gastroenterology Journal, 2020, 8, 263-270.	1.6	22
81	A Distinct Colon-Derived Breath Metabolome is Associated with Inflammatory Bowel Disease, but not its Complications. Clinical and Translational Gastroenterology, 2016, 7, e201.	1.3	21
82	Magnetisation transfer imaging adds information to conventional MRIs to differentiate inflammatory from fibrotic components of small intestinal strictures in Crohn's disease. European Radiology, 2020, 30, 1938-1947.	2.3	21
83	Quantitative Phase Imaging Using Digital Holographic Microscopy Reliably Assesses Morphology and Reflects Elastic Properties of Fibrotic Intestinal Tissue. Scientific Reports, 2019, 9, 19388.	1.6	20
84	Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis ―a unique therapeutic target in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2022, 55, 277-291.	1.9	19
85	Novel Functions of the Septin Cytoskeleton. American Journal of Pathology, 2021, 191, 40-51.	1.9	18
86	The Selective Phosphodiesterase 4 Inhibitor Roflumilast and Phosphodiesterase 3/4 Inhibitor Pumafentrine Reduce Clinical Score and TNF Expression in Experimental Colitis in Mice. PLoS ONE, 2013, 8, e56867.	1.1	17
87	Intestinal Fibrosis and Liver Fibrosis: Consequences of Chronic Inflammation or Independent Pathophysiology?. Inflammatory Intestinal Diseases, 2016, 1, 41-49.	0.8	17
88	Prevention and Treatment of Stricturing Crohn's Disease – Perspectives and Challenges. Expert Review of Gastroenterology and Hepatology, 2021, 15, 401-411.	1.4	17
89	Patients With Low Drug Levels or Antibodies to a Prior Anti–Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti–Tumor Necrosis Factor. Clinical Gastroenterology and Hepatology, 2022, 20, 465-467.e2.	2.4	17
90	Potential Role of Epithelial Endoplasmic Reticulum Stress and Anterior Gradient Protein 2 Homologue in Crohn's Disease Fibrosis. Journal of Crohn's and Colitis, 2021, 15, 1737-1750.	0.6	16

#	Article	IF	Citations
91	Mesenteric Excision and Exclusion for Ileocolic Crohn's Disease: Feasibility and Safety of an Innovative, Combined Surgical Approach With Extended Mesenteric Excision and Kono-S Anastomosis. Diseases of the Colon and Rectum, 2022, 65, e5-e13.	0.7	16
92	Intestinal proteomic analysis of a novel non-human primate model of experimental colitis reveals signatures of mitochondrial and metabolic dysfunction. Mucosal Immunology, 2019, 12, 1327-1335.	2.7	15
93	Potassium channels in intestinal epithelial cells and their pharmacological modulation: a systematic review. American Journal of Physiology - Cell Physiology, 2021, 320, C520-C546.	2.1	15
94	Use of Anticoagulation During Wireless Capsule Endoscopy for the Investigation of Recurrent Obscure Gastrointestinal Bleeding. Endoscopy, 2006, 38, 526-528.	1.0	14
95	Crohn's Disease of the Esophagus: Treatment of an Esophagobronchial Fistula with the Novel Liquid Embolic Polymer "Onyx― Zeitschrift Fur Gastroenterologie, 2006, 44, 599-602.	0.2	14
96	Time to Look Underneath the Surface: Ulcerative Colitis-Associated Fibrosis. Journal of Crohn's and Colitis, 2015, 9, 941-942.	0.6	13
97	Toward an antifibrotic therapy for inflammatory bowel disease. United European Gastroenterology Journal, 2016, 4, 493-495.	1.6	13
98	Mutual Regulation of TLR/NLR and CEACAM1 in the Intestinal Microvasculature: Implications for IBD Pathogenesis and Therapy. Inflammatory Bowel Diseases, 2019, 25, 294-305.	0.9	13
99	Mouse Models of Intestinal Fibrosis. Methods in Molecular Biology, 2021, 2299, 385-403.	0.4	13
100	Targeting anti-fibrotic pathways in Crohn's disease – The final frontier?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2019, 38-39, 101603.	1.0	12
101	Intra-Cavitary Contrast-Enhanced Ultrasound: A Novel Radiation-Free Method for Detecting Abscess-Associated Penetrating Disease in Crohnâ∈™s Disease. Journal of Crohn's and Colitis, 2019, 13, 593-599.	0.6	12
102	Mild neoterminal ileal postâ€operative recurrence of Crohn's disease conveys higher risk for severe endoscopic disease progression than isolated anastomotic lesions. Alimentary Pharmacology and Therapeutics, 2022, 55, 1139-1150.	1.9	12
103	Systematic Review: Sweet Syndrome Associated with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2021, 15, 1864-1876.	0.6	11
104	Noncoding RNAs as Promising Diagnostic Biomarkers and Therapeutic Targets in Intestinal Fibrosis of Crohnâ \in TM s Disease: The Path From Bench to Bedside. Inflammatory Bowel Diseases, 2021, 27, 971-982.	0.9	10
105	Paediatric Ulcerative Colitis Is a Fibrotic Disease and Is Linked with Chronicity of Inflammation. Journal of Crohn's and Colitis, 2022, 16, 804-821.	0.6	10
106	573 Adipocyte and Preadipocyte Derived-Mediators Induce a PRO-Fibrogenic Phenotype in Human Intestinal Mesenchymal Cells -A Novel Link Between Fat and Intestinal Fibrosis. Gastroenterology, 2014, 146, S-106.	0.6	8
107	Thiopurines and the Natural Course of Crohn's Disease: Did We Finally Find the Right Therapeutic Target?. American Journal of Gastroenterology, 2014, 109, 1037-1040.	0.2	8
108	Ileal Crohn's Disease Exhibits Similar Transmural Fibrosis Irrespective of Phenotype. Clinical and Translational Gastroenterology, 2021, 12, e00330.	1.3	8

#	Article	IF	CITATIONS
109	ROCKing the Field of Intestinal Fibrosis or Between a ROCK and a Hard Place?. Gastroenterology, 2017, 153, 895-897.	0.6	7
110	629 - Creeping-Fat Derived Free Fatty Acids Induce Hyperplasia of Intestinal Muscularis Propria Muscle Cells – A Novel Link Between Fat and Intestinal Stricture Formation in Crohn's Disease. Gastroenterology, 2018, 154, S-131.	0.6	7
111	Optimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic. Current Opinion in Gastroenterology, 2021, 37, 313-319.	1.0	7
112	Managing Intestinal Fibrosis in Patients With Inflammatory Bowel Disease. Gastroenterology and Hepatology, 2018, 14, 120-122.	0.2	7
113	A United States expert consensus to standardise definitions, followâ€up, and treatment targets for extraâ€intestinal manifestations in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2022, 55, 1179-1191.	1.9	7
114	Loss of tolerance to glycoprotein 2 isoforms 1 and 4 is associated with Crohn's disease of the pouch. Alimentary Pharmacology and Therapeutics, 2018, 48, 1251-1259.	1.9	6
115	Cooling Down the Hot Potato: Anti-Interleukin 36 Therapy Prevents and Treats Experimental Intestinal Fibrosis. Gastroenterology, 2019, 156, 871-873.	0.6	6
116	How I Approach the Management of Stricturing Crohn's Disease. American Journal of Gastroenterology, 2019, 114, 1181-1184.	0.2	6
117	Activation of Toll-Like Receptor (TLR) 5 Induces a PRO-Fibrogenic Phenotype on Human Intestinal Myofibroblasts (HIF) – A Novel Pathway Mediated by Caspase 1. Gastroenterology, 2011, 140, S-114.	0.6	5
118	598 Eosinophil Derived TGF-ß1 Activates Human Esophageal Mesenchymal Cells and Alters Esophageal Motility - Implications for Dysphagia in Eosinophilic Esophagitis (EoE). Gastroenterology, 2012, 142, S-116.	0.6	5
119	Su1869 Submucosal Fibrosis in Ulcerative Colitis Is Linked With Severity and Chronicity of Inflammation. Gastroenterology, 2016, 150, S575.	0.6	5
120	Intestinal fibrosis: The Achilles heel of inflammatory bowel diseases?. Journal of Digestive Diseases, 2020, 21, 306-307.	0.7	5
121	Application of Artificial Intelligence to Clinical Practice in Inflammatory Bowel Disease – What the Clinician Needs to Know. Journal of Crohn's and Colitis, 2022, 16, 460-471.	0.6	5
122	Hypoxia-Inducible Factor 1-Alpha Stabilizers in the Treatment of Inflammatory Bowel Diseases: Oxygen as a Novel IBD Therapy?. Journal of Crohn's and Colitis, 2022, 16, 1924-1932.	0.6	5
123	Editorial: treating strictures in inflammatory bowel disease—authors' reply. Alimentary Pharmacology and Therapeutics, 2018, 48, 1313-1314.	1.9	4
124	Serum anti-glycan-antibodies in relatives of patients with inflammatory bowel disease. PLoS ONE, 2018, 13, e0194222.	1.1	4
125	Implications of COVID-19 for patients with pre-existing digestive diseases: an update. The Lancet Gastroenterology and Hepatology, 2021, 6, 258-260.	3.7	4
126	Sall46 Efficacy, Safety and Long Term Outcome of Endoscopic Dilation Therapy for Stricturing Crohn's Disease - A Combined Analysis of 3252 Endoscopic Balloon Dilation Procedures. Gastroenterology, 2015, 148, S-239-S-240.	0.6	3

#	Article	IF	CITATIONS
127	Rising Educators, Academicians, and Clinicians Helping Inflammatory Bowel Disease (REACH-IBD)—Promoting Improvement of Inflammatory Bowel Disease Education in the United States. Inflammatory Bowel Diseases, 2016, 22, 1531-1532.	0.9	3
128	Differences in the imaging of Crohn's disease patients between North America and Europe: are we ready to bridge the divide?. Abdominal Radiology, 2019, 44, 1637-1643.	1.0	3
129	Worse outcomes and higher costs of care in fibrostenotic Crohn's disease: a real-world propensity-matched analysis in the USA. BMJ Open Gastroenterology, 2021, 8, e000781.	1.1	3
130	P160 Hypercoagulability in patients undergoing abdominopelvic surgery for inflammatory bowel disease: insights from thromboelastography. Journal of Crohn's and Colitis, 2019, 13, S168-S169.	0.6	2
131	Duodenojejunal Bypass and Strictureplasty for Diffuse Small Bowel Crohn's Disease with a Step-by-Step Visual Guide. Crohn's & Colitis 360, 2019, 1, .	0.5	2
132	Combined Immunodeficiency With Inflammatory Bowel Disease in a Patient With TTC7A Deficiency. ACG Case Reports Journal, 2019, 6, e00061.	0.2	2
133	Predicting Risk of Surgery in Patients With Small Bowel Crohn's Disease Strictures Using Computed Tomography and Magnetic Resonance Enterography. Inflammatory Bowel Diseases, 2022, , .	0.9	2
134	887 Integrated Pathways of Fibrogenesis in Eosinophilic Esophagitis: Active Secretion of Th2 Cytokines and TGF- l^2l , and Binding of Activated Eosinophils Promote Collagen I and Fibronectin Production By Human Esophageal Mesenchymal Cells. Gastroenterology, 2009, 136, A-137.	0.6	1
135	First international summit on fibrosis in intestinal inflammation: mechanisms and biological therapies. Fibrogenesis and Tissue Repair, 2010, 3, 22.	3.4	1
136	Su1824 Endoscopic Dilation for Primary Crohn's Disease Strictures in the Upper GI Tract: Efficacy, Safety and Long Term Outcome. Gastroenterology, 2016, 150, S563.	0.6	1
137	DOP073 Results of the sixth ECCO Scientific Workshop: The pathogenesis of inflammatory extraintestinal manifestations of inflammatory bowel disease: implications for research, diagnosis, and therapy. Journal of Crohn's and Colitis, 2018, 12, S080-S080.	0.6	1
138	Tu1280 SUCCESSFUL ESTABLISHMENT OF DECELLULARIZED INTESTINAL EXTRACELLULAR MATRIX 3D SCAFFOLDS WITH PRESERVED STRUCTURE, COMPONENTS AND FUNCTION. Gastroenterology, 2020, 158, S-1042.	0.6	1
139	P827 The clinical phenotype of collagenous colitis is associated with T-cell-related genetic variants. Journal of Crohn's and Colitis, 2020, 14, S642-S643.	0.6	1
140	A single-cell atlas of fibroblasts: one size does not fit all. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 595-596.	8.2	1
141	Not Hard to Swallowâ€"Understanding Endothelial-Fibroblast Crosstalk in Eosinophilic Esophagitis. Gastroenterology, 2021, , .	0.6	1
142	P182 Twisted Pouch Syndrome: A Rare, Difficult to Diagnose Mechanical Complication of Ileal Pouch-Anal Anastomosis Amenable to Redo Pouch Salvage Surgery. Journal of Crohn's and Colitis, 2022, 16, i248-i248.	0.6	1
143	Young GI Angle: Young physicians and researchers within UEG – Perspectives and a toolbox for future development. United European Gastroenterology Journal, 2016, 4, 156-157.	1.6	0
144	DOPO44 Efficacy, safety and long-term outcome of endoscopic dilation therapy for Crohn's disease strictures of the upper gastrointestinal tract: an international multicentre cohort study including 99 patients with 129 dilation procedures. Journal of Crohn's and Colitis, 2018, 12, S061-S062.	0.6	0

#	Article	IF	CITATIONS
145	Fibrosis and Stricturing Disease in Crohn's Disease. , 2019, , 73-87.		O
146	P532 Safety and efficacy of endoscopic dilation of small bowel Crohn's disease strictures by balloon-assisted enteroscopy: pooled analysis of individual data from 210 patients. Journal of Crohn's and Colitis, 2019, 13, S379-S379.	0.6	0
147	P072 Quantitative phase imaging for the characterisation of Crohn's disease-derived intestinal strictures. Journal of Crohn's and Colitis, 2019, 13, S121-S122.	0.6	O
148	P111 Cross-sectional imaging is highly sensitive in detecting endoscopic post-operative recurrence in Crohn's disease patients. Journal of Crohn's and Colitis, 2021, 15, S203-S204.	0.6	0
149	P571 Optimal biologic management of endoscopic postoperative recurrence following ileocecal resection in Crohn's disease. Journal of Crohn's and Colitis, 2021, 15, S529-S531.	0.6	O
150	No Longer Stretching Credibility: Mechanical Force Meets Inflammation in Experimental Intestinal Stenosis. Digestive Diseases and Sciences, $2021, , 1.$	1.1	0
151	Charakterisierung von Morbus Crohn-bedingten Stenosen mittels digitalholographischer Mikroskopie. , 2017, 55, .		O
152	Abdominal pain and bloody diarrhea in a 32-year-old woman. Cleveland Clinic Journal of Medicine, 2017, 84, 847-854.	0.6	0
153	Fibrostenotic Inflammatory Bowel Disease: A Cinderella Story. , 2018, , 1-4.		O
154	Endoscopic interventions for stricturing Crohn's disease. The Lancet Gastroenterology and Hepatology, 2022, , .	3.7	0
155	Editorial: shedding new light on extraintestinal manifestations in inflammatory bowel disease—authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 55, 1208-1209.	1.9	O
156	Letter: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis—a unique therapeutic target in inflammatory bowel disease. Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 55, 1360-1360.	1.9	0